<< Does anybody think that Sepracor is only worth one sixteenth of Amgen's market value? >>
Count me as one. Actually, it should be worth less at this stage of its development, hype notwithstanding. Amgen is enormously profitable, and its R&D is financed with operating earnings. Separacor is built on hope, FDA's good will (that may or may not be forthcoming), and current Wall Street enthusiasm (which seems to be rapidly deflating). Its R&D is funded, as of now and the foreseeable future, by investor charity.
Sepracor is worth buying at some price, but is it in the league of the Big Six (AMGN, BGEN, CHIR, GENZ, GNE, IMNX)? Not yet. |
